| abstract |
The present invention is directed to an oral dosage form comprising a gel capsule comprising, (a) plasticizer; (b) gelatin; (c) water; and (d) greater than 850 mg DHA ethyl ester, wherein less than about 2% (wt/wt) of the total fatty acid content of the dosage form is EPA, wherein the total weight of the capsule is about 1 g and wherein the capsule is stable at about 25° C. at 60% relative humidity. |